Launched in August for dry eye disease, Xiidra already has seen nearly 65,000 prescriptions written and has captured 16% market share in the US. Overall quarterly sales came in below Wall Street expectations for Shire, but the firm says it was a strong quarter of execution.
Shire PLC says it had another in a string of strong earnings quarters dating back to the start of 2014, but analysts are calling the quarter a miss due to lower than expected sales of legacy Baxalta Inc. products acquired in the merger of the two companies earlier this year.
In an interview, CEO Flemming Ornskov told Scrip that Shire’s third quarter was a success going by every metric he...
Eylea HD saw significant sales growth, but the company reported delays in FDA approvals for the drug and a CRL for its CD20xCD3-targeting bispecific for lymphomas.
The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
